Information Provided By:
Fly News Breaks for February 7, 2019
CVS
Feb 7, 2019 | 08:53 EDT
Morgan Stanley analyst Ricky Goldwasser noted that CVS Health will provide guidance on February 20 for the first time since completing the Aetna transaction and he puts 60% odds on initial FY19 EPS guidance of $7.00-$7.30. While such an outlook would be below the current consensus of $7.44, bears are concerned guidance could be below $7 and such an outlook would be seen as "good enough" to drive the stock up 4%-9%, Goldwasser tells investors. If initial 2019 EPS guidance is below $7.00, which is a scenario he gives a 30% probability, the stock could be down 11%. If the initial 2019 EPS guidance range has a midpoint above $7.40, which Goldwasser assigns only 10% odds of happening, the stock could be up 10%, the analyst said. He keeps an Overweight rating and $100 price target on CVS shares ahead of the company's December quarter earnings report.
News For CVS From the Last 2 Days
There are no results for your query CVS